Multifaceted role for p53 in pancreatic cancer suppression
Open accessThe DOI matches its Crossref record; 60 of the 61 references it cites were found in a registry or an index.
Abstract
The vast majority of human pancreatic ductal adenocarcinomas (PDACs) harbor TP53 mutations, underscoring p53’s critical role in PDAC suppression. PDAC can arise when pancreatic acinar cells undergo acinar-to-ductal metaplasia (ADM), giving rise to premalignant pancreatic intraepithelial neoplasias (PanINs), which finally progress to PDAC. The occurrence of TP53 mutations in late-stage PanINs has led to the idea that p53 acts to suppress malignant transformation of PanINs to PDAC. However, the cellular basis for p53 action during PDAC development has not been explored in detail. Here, we leverage a hyperactive p53 variant—p53 53,54 —which we previously showed is a more robust PDAC suppressor than wild-type p53, to elucidate how p53 acts at the cellular level to dampen PDAC development. Using both inflammation-induced and KRAS G12D -driven PDAC models, we find that p53 53,54 both limits ADM accumulation and suppresses PanIN cell proliferation and does so more effectively than wild-type p53. Moreover, p53 53,54 suppresses KRAS signaling in PanINs and limits effects on the extracellular matrix (ECM) remodeling. While p53 53,54 has highlighted these functions, we find that pancreata in wild-type p53 mice similarly show less ADM, as well as reduced PanIN cell proliferation, KRAS signaling, and ECM remodeling relative to Trp53 -null mice. We find further that p53 enhances chromatin accessibility at sites controlled by acinar cell identity transcription factors. These findings reveal that p53 acts at multiple stages to suppress PDAC, both by limiting metaplastic transformation of acini and by dampening KRAS signaling in PanINs, thus providing key new understanding of p53 function in PDAC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“TP53 mutations, found in 50–90% of pancreatic ductal adenocarcinomas, significantly affect carcinogenesis, prognosis and treatment response [17,21,34,35].”
From Significance of TP53, CDKN2A, SMAD4 and KRAS in Pancreatic Cancer (2024) · cites this paper as [17]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“TP53 mutations, detected in 60–70% of cases, play a crucial role in suppressing malignant transformation, affecting carcinogenesis and prognosis [17,36].”
From Significance of TP53, CDKN2A, SMAD4 and KRAS in Pancreatic Cancer (2024) · cites this paper as [17]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“TP53’s multifaceted roles include limiting preneoplastic lesion development, regulating their character and influencing the tumor microenvironment to restrain invasive cancer progression [17].”
From Significance of TP53, CDKN2A, SMAD4 and KRAS in Pancreatic Cancer (2024) · cites this paper as [17]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Mutations occur in late-stage PanINs, indicating the p53’s role in inhibiting transformation into PDAC.”
From Significance of TP53, CDKN2A, SMAD4 and KRAS in Pancreatic Cancer (2024) · cites this paper as [17]
The cited source says what the claim attributes to it.
In the citing paper
“In mouse models, intact p53 protects against pancreatic cancer progression, confirming its role in suppressing malignant transformation [17,29,36].”
From Significance of TP53, CDKN2A, SMAD4 and KRAS in Pancreatic Cancer (2024) · cites this paper as [17]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2
Love, M. I., Huber, W., & Anders, S. (2014) · Genome Biology · doi:10.1186/s13059-014-0550-8 · Cited by 95,106 · cited 1×
“2211937120 9 of 9 To assess differential accessibility, DESeq2 was applied (60) using a model to account for mouse model, cell type, and batch.”
Fast gapped-read alignment with Bowtie 2
Langmead, B., & Salzberg, S. L. (2012) · Nature Methods · doi:10.1038/nmeth.1923 · Cited by 56,400 · cited 1×
“FASTQ files were aligned to the mouse genome mm10 using bowtie (56).”
MethodHeinz, S., Benner, C., Spann, N., Bertolino, E., Lin, Y. C., Laslo, P., Cheng, J. X., Murre, C., Singh, H., & Glass, C. K. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.05.004 · Cited by 13,382 · cited 1×
“Peaks with significant changes in accessibility between p53-proficient and deficient acinar cells were further analyzed for motif enrichment using the program HOMER (61).”
MethodBuenrostro, J. D., Giresi, P. G., Zaba, L. C., Chang, H. Y., & Greenleaf, W. J. (2013) · Nature Methods · doi:10.1038/nmeth.2688 · Cited by 6,422 · cited 2×
“To create sequencing libraries, transposed DNA was amplified and indexed with Illumina Nextera sequencing primers as previously described (55).”
MethodSelf-citationHingorani, S. R., Wang, L., Multani, A. S., Combs, C., Deramaudt, T. B., Hruban, R. H., Rustgi, A. K., Chang, S., & Tuveson, D. A. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.04.023 · Cited by 2,609
Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse
Hingorani, S. R., Petricoin, E. F., Maitra, A., Rajapakse, V., King, C., Jacobetz, M. A., Ross, S., Conrads, T. P., Veenstra, T. D., Hitt, B. A., et al. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00309-x · Cited by 2,471 · cited 4×
“p53(53,54) (27, 28) and p53 mice (50) were bred to a mouse model for pancreatic cancer carrying Kras (51) and a Ptf1a allele (6) that induces the expression of mutant Kras specifically in the pancreas.”
BackgroundMethodInfluentialIntegrated genomic characterization of pancreatic ductal adenocarcinoma
Raphael, B. J., Hruban, R. H., Aguirre, A. J., Moffitt, R. A., Yeh, J. J., Stewart, C., Robertson, A. G., Cherniack, A. D., Gupta, M., Getz, G., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.07.007 · Cited by 2,019 · cited 1×
“After KRAS, mutations in the TP53, CDKN2A, and SMAD4 tumor suppressor genes (TSGs) are the most prevalent in human PDAC, with estimated mutation frequencies of 72, 30, and 32%, respectively (17).”
BackgroundAnalysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras
Jackson, E. L., Willis, N., Mercer, K., Bronson, R. T., Crowley, D., Montoya, R., Jacks, T., & Tuveson, D. A. (2001) · Genes & Development · doi:10.1101/gad.943001 · Cited by 1,898 · cited 19×
“Wild-Type p53 Restrains ADM and PanINs in Aging KrasG12D Mice.”
BackgroundInfluentialPark, W., Chawla, A., & O’Reilly, E. M. (2021) · JAMA · doi:10.1001/jama.2021.13027 · Cited by 1,882
Genetics and biology of pancreatic ductal adenocarcinoma
Hezel, A. F., Kimmelman, A. C., Stanger, B. Z., Bardeesy, N., & DePinho, R. A. (2006) · Genes & Development · doi:10.1101/gad.1415606 · Cited by 1,577
Unravelling mechanisms of p53-mediated tumour suppression
Bieging, K. T., Mello, S. S., & Attardi, L. D. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3711 · Cited by 1,387 · cited 2×
“Despite being the most commonly-mutated gene in human cancer, the mechanisms by which p53 impedes tumor development remain incompletely understood. p53 is a transcriptional activator known to limit cell cycle progression or induce apoptosis in response to acute DNA damage, and it does so by transcriptionally activatin…”
BackgroundSelf-citationSuppression of induced pluripotent stem cell generation by the p53–p21 pathway
Hong, H., Takahashi, K., Ichisaka, T., Aoi, T., Kanagawa, O., Nakagawa, M., Okita, K., & Yamanaka, S. (2009) · Nature · doi:10.1038/nature08235 · Cited by 1,301
Guerra, C., Schuhmacher, A. J., Cañamero, M., Grippo, P. J., Verdaguer, L., Pérez-Gallego, L., Dubus, P., Sandgren, E. P., & Barbacid, M. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.01.012 · Cited by 1,224
Pancreatic cancer biology and genetics
Bardeesy, N., & DePinho, R. A. (2002) · Nature Reviews Cancer · doi:10.1038/nrc949 · Cited by 1,142 · cited 4×
“In particular, understanding how p53 acts, given its mutation in nearly 75% of PDACs, will provide great insight into PDAC development.”
BackgroundInfluentialLinking the p53 tumour suppressor pathway to somatic cell reprogramming
Kawamura, T., Suzuki, J., Wang, Y. V., Menendez, S., Morera, L. B., Raya, A., Wahl, G. M., & Belmonte, J. C. I. (2009) · Nature · doi:10.1038/nature08311 · Cited by 1,115
A p53-mediated DNA damage response limits reprogramming to ensure iPS cell genomic integrity
Marión, R. M., Strati, K., Li, H., Murga, M., Blanco, R., Ortega, S., Fernandez-Capetillo, O., Serrano, M., & Blasco, M. A. (2009) · Nature · doi:10.1038/nature08287 · Cited by 1,028
Marino, S., Vooijs, M., van der Gulden, H., Jonkers, J., & Berns, A. (2000) · Genes & Development · doi:10.1101/gad.14.8.994 · Cited by 920 · cited 1×
“p53(53,54) (27, 28) and p53 mice (50) were bred to a mouse model for pancreatic cancer carrying Kras (51) and a Ptf1a allele (6) that induces the expression of mutant Kras specifically in the pancreas.”
BackgroundTumor Suppression in the Absence of p53-Mediated Cell-Cycle Arrest, Apoptosis, and Senescence
Li, T., Kon, N., Jiang, L., Tan, M., Ludwig, T., Zhao, Y., Baer, R., & Gu, W. (2012) · Cell · doi:10.1016/j.cell.2012.04.026 · Cited by 912
KRAS: The Critical Driver and Therapeutic Target for Pancreatic Cancer
Waters, A. M., & Der, C. J. (2018) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a031435 · Cited by 875
Oncogenic Kras is required for both the initiation and maintenance of pancreatic cancer in mice
Collins, M. A., Bednar, F., Zhang, Y., Brisset, J.-C., Galbán, S., Galbán, C. J., Rakshit, S., Flannagan, K. S., Adsay, N. V., & Pasca di Magliano, M. (2012) · Journal of Clinical Investigation · doi:10.1172/jci59227 · Cited by 770 · cited 2×
“PanINs can be accompanied by extracellular matrix (ECM) remodeling (33, 34).”
BackgroundPresence of Somatic Mutations in Most Early-Stage Pancreatic Intraepithelial Neoplasia
Kanda, M., Matthaei, H., Wu, J., Hong, S., Yu, J., Borges, M., Hruban, R. H., Maitra, A., Kinzler, K., Vogelstein, B., et al. (2012) · Gastroenterology · doi:10.1053/j.gastro.2011.12.042 · Cited by 741 · cited 1×
“Moreover, the detection of oncogenic KRAS mutations in human acinar cells and early PanIN1 lesions supports the notion that KRAS mutations also drive ADM, PanINs, and PDAC development in humans (13, 15, 16).”
BackgroundKopp, J. L., von Figura, G., Mayes, E., Liu, F.-F., Dubois, C. L., Morris, J. P., Pan, F. C., Akiyama, H., Wright, C. V. E., Jensen, K., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.10.025 · Cited by 697
Mutant p53 drives metastasis and overcomes growth arrest/senescence in pancreatic cancer
Morton, J. P., Timpson, P., Karim, S. A., Ridgway, R. A., Athineos, D., Doyle, B., Jamieson, N. B., Oien, K. A., Lowy, A. M., Brunton, V. G., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0908428107 · Cited by 657 · cited 1×
“This response reflects a more classical p53 function in dampening cell proliferation, and indeed, previous studies have suggested that the tumor suppressive capacity of p53 in pancreatic cancer lies in its ability to trigger senescence in PanIN lesions (41).”
Distinct p53 Transcriptional Programs Dictate Acute DNA-Damage Responses and Tumor Suppression
Brady, C. A., Jiang, D., Mello, S. S., Johnson, T. M., Jarvis, L. A., Kozak, M. M., Broz, D. K., Basak, S., Park, E. J., McLaughlin, M. E., et al. (2011) · Cell · doi:10.1016/j.cell.2011.03.035 · Cited by 533 · cited 1×
“p53(53,54) (27, 28) and p53 mice (50) were bred to a mouse model for pancreatic cancer carrying Kras (51) and a Ptf1a allele (6) that induces the expression of mutant Kras specifically in the pancreas.”
BackgroundSelf-citationGenetics and biology of pancreatic ductal adenocarcinoma
Ying, H., Dey, P., Yao, W., Kimmelman, A. C., Draetta, G. F., Maitra, A., & DePinho, R. A. (2016) · Genes & Development · doi:10.1101/gad.275776.115 · Cited by 527
Guerra, C., Collado, M., Navas, C., Schuhmacher, A. J., Hernández-Porras, I., Cañamero, M., Rodriguez-Justo, M., Serrano, M., & Barbacid, M. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.05.011 · Cited by 516 · cited 1×
“We then analyzed the early steps of PDAC development by subjecting mice to treatment with caerulein, an oligopeptide that stimulates secretion of digestive enzymes and causes acute pancreatitis, thereby enhancing ADM and PanIN formation (14).”
BackgroundLOLA: enrichment analysis for genomic region sets and regulatory elements in R and Bioconductor
Sheffield, N. C., & Bock, C. (2016) · Bioinformatics · doi:10.1093/bioinformatics/btv612 · Cited by 454
Maitra, A., Adsay, N. V., Argani, P., Iacobuzio-Donahue, C., De Marzo, A., Cameron, J. L., Yeo, C. J., & Hruban, R. H. (2003) · Modern Pathology · doi:10.1097/01.mp.0000086072.56290.fb · Cited by 429 · cited 1×
“Moreover, TP53 mutations in PanIN3 were largely inferred by immunostaining for p53 protein (25), but this provides only an indirect assessment of TP53 status, as positivity can reflect either accumulation of mutant p53 or stabilization of wild-type p53 in response to a stress signal.”
BackgroundStellaTUM: current consensus and discussion on pancreatic stellate cell research
Erkan, M., Adler, G., Apte, M. V., Bachem, M. G., Buchholz, M., Detlefsen, S., Esposito, I., Friess, H., Gress, T. M., Habisch, H.-J., et al. (2012) · Gut · doi:10.1136/gutjnl-2011-301220 · Cited by 410
Mazur, P. K., Herner, A., Mello, S. S., Wirth, M., Hausmann, S., Sánchez-Rivera, F. J., Lofgren, S. M., Kuschma, T., Hahn, S. A., Vangala, D., et al. (2015) · Nature Medicine · doi:10.1038/nm.3952 · Cited by 397 · cited 1×
“In this assay, we used TGFα/EGF to induce ADM, as previously described (32), and we tested whether p53(53,54) can inhibit ADM in vitro, without the interference of other factors present in vivo, such as inflammation and the presence of stromal cells.”
MethodSelf-citationSMYD3 links lysine methylation of MAP3K2 to Ras-driven cancer
Mazur, P. K., Reynoird, N., Khatri, P., Jansen, P. W. T. C., Wilkinson, A. W., Liu, S., Barbash, O., Van Aller, G. S., Huddleston, M., Dhanak, D., et al. (2014) · Nature · doi:10.1038/nature13320 · Cited by 391 · cited 1×
“Acinar cultures from p53 and p53 mice (n = 4 for each cohort) were established from 4- to 8-wk–old p53 and p53 mice by modification of previously published protocols (53, 54).”
MethodSelf-citationMorris, J. P., Cano, D. A., Sekine, S., Wang, S. C., & Hebrok, M. (2010) · Journal of Clinical Investigation · doi:10.1172/jci40045 · Cited by 366
Recapitulation of elements of embryonic development in adult mouse pancreatic regeneration
Jensen, J. N., Cameron, E., Garay, M. V. R., Starkey, T. W., Gianani, R., & Jensen, J. (2005) · Gastroenterology · doi:10.1053/j.gastro.2004.12.008 · Cited by 353 · cited 1×
“For pancreatitis experiments, the mice were aged for 2 mo and treated with caerulein (100 μg per kilogram of body weight; Sigma-Aldrich) over 2 d, as previously described (52).”
MethodMeans, A. L., Meszoely, I. M., Suzuki, K., Miyamoto, Y., Rustgi, A. K., Coffey, R. J., Wright, C. V. E., Stoffers, D. A., & Leach, S. D. (2005) · Development · doi:10.1242/dev.01925 · Cited by 344 · cited 1×
“Acinar cultures from p53 and p53 mice (n = 4 for each cohort) were established from 4- to 8-wk–old p53 and p53 mice by modification of previously published protocols (53, 54).”
MethodImproved peak-calling with MACS2
Gaspar, J. M. (2018) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/496521 · Cited by 301
α-Ketoglutarate links p53 to cell fate during tumour suppression
Morris, J. P., Yashinskie, J. J., Koche, R., Chandwani, R., Tian, S., Chen, C.-C., Baslan, T., Marinkovic, Z. S., Sánchez-Rivera, F. J., Leach, S. D., et al. (2019) · Nature · doi:10.1038/s41586-019-1577-5 · Cited by 296 · cited 1×
“This role for p53 in restricting ADM accumulation is in keeping with the previously described ability of p53 to impede reprogramming of differentiated cells to iPS cells (36–38), as well as with studies showing that p53 restricts cellular plasticity and enforces cell fate when suppressing liver and pancreatic cancer (…”
BackgroundValente, L. J., Gray, D. H. D., Michalak, E. M., Pinon-Hofbauer, J., Egle, A., Scott, C. L., Janic, A., & Strasser, A. (2013) · Cell Reports · doi:10.1016/j.celrep.2013.04.012 · Cited by 291
Stage-specific sensitivity to p53 restoration during lung cancer progression
Feldser, D. M., Kostova, K. K., Winslow, M. M., Taylor, S. E., Cashman, C., Whittaker, C. A., Sanchez-Rivera, F. J., Resnick, R., Bronson, R., Hemann, M. T., et al. (2010) · Nature · doi:10.1038/nature09535 · Cited by 273 · cited 1×
“Of note, dampened KRAS signaling in the presence of p53 has been observed in other contexts, such as in mouse lung adenocarcinoma models (43, 44).”
BackgroundEpithelial memory of inflammation limits tissue damage while promoting pancreatic tumorigenesis
Del Poggetto, E., Ho, I.-L., Balestrieri, C., Yen, E.-Y., Zhang, S., Citron, F., Shah, R., Corti, D., Diaferia, G. R., Li, C.-Y., et al. (2021) · Science · doi:10.1126/science.abj0486 · Cited by 253 · cited 1×
“Moreover, the detection of oncogenic KRAS mutations in human acinar cells and early PanIN1 lesions supports the notion that KRAS mutations also drive ADM, PanINs, and PDAC development in humans (13, 15, 16).”
BackgroundLüttges, J., Galehdari, H., Bröcker, V., Schwarte-Waldhoff, I., Henne-Bruns, D., Klöppel, G., Schmiegel, W., & Hahn, S. A. (2001) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64123-5 · Cited by 241 · cited 3×
“The idea that p53 exerts tumor suppressive effects in PanINs is consistent with the fact that LOH of TP53 is a late event in PDAC progression, observed in advanced PanINs, and is thought to be essential for the progression from PanINs to PDAC (19).”
BackgroundResultp53-Dependent Nestin Regulation Links Tumor Suppression to Cellular Plasticity in Liver Cancer
Tschaharganeh, D. F., Xue, W., Calvisi, D. F., Evert, M., Michurina, T. V., Dow, L. E., Banito, A., Katz, S. F., Kastenhuber, E. R., Weissmueller, S., et al. (2014) · Cell · doi:10.1016/j.cell.2014.05.051 · Cited by 227 · cited 1×
“This role for p53 in restricting ADM accumulation is in keeping with the previously described ability of p53 to impede reprogramming of differentiated cells to iPS cells (36–38), as well as with studies showing that p53 restricts cellular plasticity and enforces cell fate when suppressing liver and pancreatic cancer (…”
Ordered and deterministic cancer genome evolution after p53 loss
Baslan, T., Morris, J. P., Zhao, Z., Reyes, J., Ho, Y.-J., Tsanov, K. M., Bermeo, J., Tian, S., Zhang, S., Askan, G., et al. (2022) · Nature · doi:10.1038/s41586-022-05082-5 · Cited by 221 · cited 5×
“Notably, a recent study using a PDAC mouse model in which p53 LOH could be measured with a fluorescent reporter showed that p53 LOH was observed in ADMs, supporting the importance of p53 tumor suppressive action in ADMs (35).”
BackgroundInfluentialRelevance of the p53–MDM2 axis to aging
Wu, D., & Prives, C. (2018) · Cell Death & Differentiation · doi:10.1038/cdd.2017.187 · Cited by 215
Murphy, S. J., Hart, S. N., Lima, J. F., Kipp, B. R., Klebig, M., Winters, J. L., Szabo, C., Zhang, L., Eckloff, B. W., Petersen, G. M., et al. (2013) · Gastroenterology · doi:10.1053/j.gastro.2013.07.049 · Cited by 199 · cited 1×
“Importantly, reports suggest that TP53 heterozygous mutations are also observed in early pancreatic lesions, such as in ADM and PanIN1A/1B stages, supporting our hypothesis that p53 function is also critical at earlier time points (19, 21, 23, 42).”
BackgroundA p53 Super-tumor Suppressor Reveals a Tumor Suppressive p53-Ptpn14-Yap Axis in Pancreatic Cancer
Mello, S. S., Valente, L. J., Raj, N., Seoane, J. A., Flowers, B. M., McClendon, J., Bieging-Rolett, K. T., Lee, J., Ivanochko, D., Kozak, M. M., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.09.007 · Cited by 179 · cited 6×
“To this end, we aged KC;Trp53 and KC;Trp53 mice for 5 mo, a time point when premalignant lesions but not cancer are typically observed (28).”
BackgroundMethodResultInfluentialSelf-citationHosoda, W., Chianchiano, P., Griffin, J. F., Pittman, M. E., Brosens, L. A., Noë, M., Yu, J., Shindo, K., Suenaga, M., Rezaee, N., et al. (2017) · The Journal of Pathology · doi:10.1002/path.4884 · Cited by 159 · cited 2×
“Mutations in these TSGs have been suggested to occur subsequent to KRAS mutations, during the progression of lower-grade PanINs to higher-grade PanINs or PDAC (18).”
BackgroundResultSelf-citationFerreira, R. M. M., Sancho, R., Messal, H. A., Nye, E., Spencer-Dene, B., Stone, R. K., Stamp, G., Rosewell, I., Quaglia, A., & Behrens, A. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.09.093 · Cited by 130
Heinmöller, E., Dietmaier, W., Zirngibl, H., Heinmöller, P., Scaringe, W., Jauch, K.-W., Hofstädter, F., & Rüschoff, J. (2000) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64520-8 · Cited by 121
Sánchez-Castillo, M., Ruau, D., Wilkinson, A. C., Ng, F. S. L., Hannah, R., Diamanti, E., Lombard, P., Wilson, N. K., & Gottgens, B. (2015) · Nucleic Acids Research · doi:10.1093/nar/gku895 · Cited by 119 · cited 1×
“LOLA (62) was used to compute enrichment of regions annotated in the CODEX database (63) in differentially accessible 1 kb tiling regions that exhibited lower accessibility in p53-deficient acinar cells than in p53-proficient acinar cells.”
MethodCell of origin influences pancreatic cancer subtype
Flowers, B. M., Xu, H., Mulligan, A. S., Hanson, K. J., Seoane, J. A., Vogel, H., Curtis, C., Wood, L. D., & Attardi, L. D. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0633 · Cited by 118
Self-citationDysfunction of the MDM2/p53 axis is linked to premature aging
Lessel, D., Wu, D., Trujillo, C., Ramezani, T., Lessel, I., Alwasiyah, M. K., Saha, B., Hisama, F. M., Rading, K., Goebel, I., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci92171 · Cited by 86
The role of p53 in developmental syndromes
Bowen, M. E., & Attardi, L. D. (2019) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjy087 · Cited by 86
Self-citationReviving the guardian of the genome: Small molecule activators of p53
Nguyen, D., Liao, W., Zeng, S. X., & Lu, H. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.03.013 · Cited by 79
Acinar cell clonal expansion in pancreas homeostasis and carcinogenesis
Neuhöfer, P., Roake, C. M., Kim, S. J., Lu, R. J., West, R. B., Charville, G. W., & Artandi, S. E. (2021) · Nature · doi:10.1038/s41586-021-03916-2 · Cited by 64 · cited 1×
“Moreover, the detection of oncogenic KRAS mutations in human acinar cells and early PanIN1 lesions supports the notion that KRAS mutations also drive ADM, PanINs, and PDAC development in humans (13, 15, 16).”
BackgroundSelf-citationA Case of Mistaken Identity? Nonductal Origins of Pancreatic “Ductal” Cancers
Murtaugh, L. C., & Leach, S. D. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.02.020 · Cited by 54
Gansauge, S., Schmid, R. M., Muller, J., Adler, G., Mattfeldt, T., & Beger, H. G. (1998) · British journal of surgery · doi:10.1046/j.1365-2168.1998.00630.x · Cited by 42 · cited 1×
“Importantly, reports suggest that TP53 heterozygous mutations are also observed in early pancreatic lesions, such as in ADM and PanIN1A/1B stages, supporting our hypothesis that p53 function is also critical at earlier time points (19, 21, 23, 42).”
Backgroundp53 deficiency triggers dysregulation of diverse cellular processes in physiological oxygen
Valente, L. J., Tarangelo, A., Li, A. M., Naciri, M., Raj, N., Boutelle, A. M., Li, Y., Mello, S. S., Bieging-Rolett, K. T., DeBerardinis, R. J., et al. (2020) · The Journal of Cell Biology · doi:10.1083/jcb.201908212 · Cited by 38
Self-citationCicchini, M., Buza, E. L., Sagal, K. M., Gudiel, A. A., Durham, A. C., & Feldser, D. M. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.01.069 · Cited by 35
Baumgart, M., Werther, M., Bockholt, A., Scheurer, M., Rüschoff, J., Dietmaier, W., Ghadimi, B. M., & Heinmöller, E. (2010) · Pancreas · doi:10.1097/mpa.0b013e3181dc62f6 · Cited by 29 · cited 1×
“Importantly, reports suggest that TP53 heterozygous mutations are also observed in early pancreatic lesions, such as in ADM and PanIN1A/1B stages, supporting our hypothesis that p53 function is also critical at earlier time points (19, 21, 23, 42).”
BackgroundGuilty as CHARGED: p53's expanding role in disease
Van Nostrand, J. L., & Attardi, L. D. (2014) · Cell Cycle · doi:10.4161/15384101.2014.987627 · Cited by 23
Self-citation
Research works printed but not linked: 2
- Cancer Genome Atlas Research Network, Integrated genomic characterization of pancreatic ductal adenocarcinoma. Cancer Cell 32, 185– 203.e113 (2017). 28810144 PMC5964983
- S. S. Mello, F. Müller, S. K. Denny, W. J. Greenleaf, L. D. Attardi, The role of p53 in pancreatic cancer suppression. GEO. https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE224744. Deposited 7 February 2023. PMC10013849 36848578
Cited by
Chromatin accessibility: biological functions, molecular mechanisms and therapeutic application
Chen, Y., Liang, R., Li, Y., Jiang, L., Ma, D., Luo, Q., & Song, G. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02030-9 · Cited by 223
Significance of TP53, CDKN2A, SMAD4 and KRAS in Pancreatic Cancer
Stefanoudakis, D., Frountzas, M., Schizas, D., Michalopoulos, N. V., Drakaki, A., & Toutouzas, K. G. (2024) · Current Issues in Molecular Biology · doi:10.3390/cimb46040177 · Cited by 110
“TP53 mutations, detected in 60–70% of cases, play a crucial role in suppressing malignant transformation, affecting carcinogenesis and prognosis [17,36].”
BackgroundInfluentialMARSTRAND-DAUCE, L., Lorenzo, D., Chassac, A., Nicole, P., Couvelard, A., & Haumaître, C. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24129946 · Cited by 119
“Recently, a “super-tumor suppressor” P53 mutant was found to inhibit ADM and PanIN proliferation driven by KrasG12D [162].”
BackgroundDecoding p53 tumor suppression: a crosstalk between genomic stability and epigenetic control?
Janic, A., Abad, E., & Amelio, I. (2024) · Cell Death and Differentiation · doi:10.1038/s41418-024-01259-9 · Cited by 100
Laila, U. E., An, W., & Xu, Z.-X. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1448489 · Cited by 39
Metadata
- Authors
- Mello, S. S., Flowers, B. M., Mazur, P. K., Lee, J. J., Müller, F., Denny, S. K., Ferreira, S., Hanson, K., Kim, S. K., Greenleaf, W. J., Wood, L. D., & Attardi, L. D.
- Affiliations
- University of Rochester Medicine (US)
- Stanford Medicine (US)
- The University of Texas MD Anderson Cancer Center (US)
- Johns Hopkins University (US)
- Corresponding author
- Attardi, Laura D.
- ORCID
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2023-02-27
- Volume
- 120
- Issue
- 10
- Pages
- e2211937120-e2211937120
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC10013849
- OpenAlex
- W4322421452
- Cited by
- 55
- References
- 61
- Citations by year
- 2026: 18 · 2025: 17 · 2024: 16 · 2023: 4
- FWCI
- 6.71
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Digital Commons-TMC (Texas Medical Center) (submittedVersion)
- Funders
- HHS | NIH | National Cancer Institute (R21 CA169673, R01 CA140875, R35 CA197591)
- Topics
- Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Signaling Pathways in Disease
- Keywords
- p53, pancreatic ductal adenocarcinoma, TP53 mutation, acinar-to-ductal metaplasia, pancreatic intraepithelial neoplasia, KRAS G12D, KRAS signaling, extracellular matrix remodeling, chromatin accessibility, premalignant pancreatic lesions, tumor suppression
- MeSH terms
- Animals, Anophthalmos, Humans, Lung Diseases, Metaplasia, Microphthalmos, Pancreas, Pancreatic Neoplasms, Precancerous Conditions, Tumor Suppressor Protein p53, Proto-Oncogene Proteins p21(ras), Mice, Knockout, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.